Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

Adult-onset growth hormone insufficiency affects quality of life, body composition, and metabolic health, but the optimal treatment approach has been debated. This review by Walker made the case for sermorelin as a superior approach to managing this condition compared to direct growth hormone replacement.

The author compared sermorelin's mechanism of action, physiological effects, and safety profile against direct growth hormone administration for treating adult-onset growth hormone insufficiency. The analysis considered both the clinical outcomes and the biological advantages of stimulating the body's own growth hormone production versus supplying exogenous hormone.

The review presented compelling arguments for sermorelin as a more physiological alternative to direct GH replacement. By stimulating the pituitary to release growth hormone through natural feedback-regulated pathways, sermorelin avoids the supraphysiological hormone levels and disrupted feedback loops that can occur with direct GH injection.

For patients with adult-onset growth hormone insufficiency, sermorelin offers an approach that works with the body's natural regulatory systems rather than overriding them. This physiological advantage, combined with a favorable safety profile, supports sermorelin as a preferred first-line option for restoring healthy growth hormone function in adults.